Home World News FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for... World News FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma By Ogkologos - September 30, 2026 71 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IGNYTE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced... August 30, 2024 TRACERx EVO, a new programme to transform lung cancer research November 9, 2022 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... January 22, 2026 Load more HOT NEWS First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies Changes in Metabolism Help Melanomas Spread